Details for Patent: 10,563,259
✉ Email this page to a colleague
Which drugs does patent 10,563,259 protect, and when does it expire?
Patent 10,563,259 protects BYSANTI and is included in one NDA.
This patent has sixteen patent family members in seven countries.
Summary for Patent: 10,563,259
| Title: | Method of treatment based on polymorphisms of the KCNQ1 gene |
| Abstract: | The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation. |
| Inventor(s): | Curt D. Wolfgang, Mihael H. Polymeropoulos |
| Assignee: | Vanda Pharmaceuticals Inc |
| Application Number: | US15/705,048 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,563,259
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-001 | Feb 20, 2026 | RX | Yes | Yes | 10,563,259 | ⤷ Start Trial | METHOD FOR ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-001 | Feb 20, 2026 | RX | Yes | Yes | 10,563,259 | ⤷ Start Trial | METHOD FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-002 | Feb 20, 2026 | RX | Yes | No | 10,563,259 | ⤷ Start Trial | METHOD FOR ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-002 | Feb 20, 2026 | RX | Yes | No | 10,563,259 | ⤷ Start Trial | METHOD FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING MILSAPERIDONE TO A PATIENT BY LOWERING THE DOSE AFTER DETERMINING THAT THE PATIENT HAS A GENETIC PREDISPOSITION FOR QT PROLONGATION | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,563,259
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2757713 | ⤷ Start Trial | |||
| European Patent Office | 2417267 | ⤷ Start Trial | |||
| European Patent Office | 3023506 | ⤷ Start Trial | |||
| European Patent Office | 3354753 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
